Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Nora Pashayan¹, Antonis C Antoniou², Urska Ivanus³, Laura J Esserman⁴, Douglas F Easton², David French⁵, Gaby Sroczynski^{6

7}, Per Hall^{8

9}, Jack Cuzick¹⁰, D Gareth Evans¹¹, Jacques Simard¹², Montserrat Garcia-Closas¹³, Rita Schmutzler¹⁴, Odette Wegwarth¹⁵, Paul Pharoah^{2

16}, Sowmiya Moorthie¹⁷, Sandrine De Montgolfier¹⁸, Camille Baron¹⁹, Zdenko Herceg²⁰, Clare Turnbull²¹, Corinne Balleyguier²², Paolo Giorgi Rossi²³, Jelle Wesseling²⁴, David Ritchie²⁵, Marc Tischkowitz²⁶, Mireille Broeders²⁷, Dan Reisel²⁸, Andres Metspalu²⁹, Thomas Callender¹, Harry de Koning³⁰, Peter Devilee³¹, Suzette Delaloge³², Marjanka K Schmidt²⁴, Martin Widschwendter^{33

34

35}

Affiliations

¹ Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.
² Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
³ Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
⁴ Carol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
⁵ Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
⁶ Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
⁷ Division of Health Technology Assessment, Oncotyrol - Center for Personalized Cancer Medicine, Innsbruck, Austria.
⁸ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁹ Department of Oncology, Södersjukhuset, Stockholm, Sweden.
¹⁰ Wolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.
¹¹ Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
¹² Genomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.
¹³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
¹⁴ Center of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.
¹⁵ Max Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.
¹⁶ Department of Oncology, University of Cambridge, Cambridge, UK.
¹⁷ PHG Foundation, Cambridge, UK.
¹⁸ IRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.
¹⁹ Unicancer, Paris, France.
²⁰ Epigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.
²¹ Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
²² Department Medical Imaging, Institut Gustave Roussy, Villejuif, France.
²³ Epidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
²⁴ Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
²⁵ Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
²⁶ Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
²⁷ Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
²⁸ Department of Women's Cancer, Institute for Women's Health, University College London, London, UK.
²⁹ The Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
³⁰ Department of Public Health, Erasmus MC, Rotterdam, Netherlands.
³¹ Department of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.
³² Breast Cancer Department, Gustave Roussy Institute, Paris, France.
³³ Department of Women's Cancer, Institute for Women's Health, University College London, London, UK. M.Widschwendter@ucl.ac.uk.
³⁴ Universität Innsbruck, Innsbruck, Austria. M.Widschwendter@ucl.ac.uk.
³⁵ European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria. M.Widschwendter@ucl.ac.uk.

PMID: 32601456
PMCID: PMC7962565
DOI: 10.1038/s41571-020-0412-0

Published Erratum

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Nora Pashayan et al. Nat Rev Clin Oncol. 2020 Nov.

. 2020 Nov;17(11):716.

doi: 10.1038/s41571-020-0412-0.

Authors

Affiliations

¹ Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.
² Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
³ Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
⁴ Carol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
⁵ Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
⁶ Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
⁷ Division of Health Technology Assessment, Oncotyrol - Center for Personalized Cancer Medicine, Innsbruck, Austria.
⁸ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁹ Department of Oncology, Södersjukhuset, Stockholm, Sweden.
¹⁰ Wolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.
¹¹ Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
¹² Genomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.
¹³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
¹⁴ Center of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.
¹⁵ Max Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.
¹⁶ Department of Oncology, University of Cambridge, Cambridge, UK.
¹⁷ PHG Foundation, Cambridge, UK.
¹⁸ IRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.
¹⁹ Unicancer, Paris, France.
²⁰ Epigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.
²¹ Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
²² Department Medical Imaging, Institut Gustave Roussy, Villejuif, France.
²³ Epidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
²⁴ Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
²⁵ Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
²⁶ Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
²⁷ Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
²⁸ Department of Women's Cancer, Institute for Women's Health, University College London, London, UK.
²⁹ The Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
³⁰ Department of Public Health, Erasmus MC, Rotterdam, Netherlands.
³¹ Department of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.
³² Breast Cancer Department, Gustave Roussy Institute, Paris, France.
³³ Department of Women's Cancer, Institute for Women's Health, University College London, London, UK. M.Widschwendter@ucl.ac.uk.
³⁴ Universität Innsbruck, Innsbruck, Austria. M.Widschwendter@ucl.ac.uk.
³⁵ European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria. M.Widschwendter@ucl.ac.uk.

PMID: 32601456
PMCID: PMC7962565
DOI: 10.1038/s41571-020-0412-0

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Pashayan N, et al. Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub 2020 Jun 18. Nat Rev Clin Oncol. 2020. PMID: 32555420 Free PMC article. Review.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Affiliations

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Authors

Affiliations

Abstract

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources